Prescription patterns of new use of fixed-dose combination inhalers in patients with chronic obstructive pulmonary disease: long-acting β2 agonists plus long-acting …
PA Liao, SW Pan, CY Chen, CY Deng… - International Journal of …, 2023 - Taylor & Francis
Background The clinical guideline recommends use of long-acting β2 agonists/long-acting
muscarinic antagonists (LABA/LAMA) or long-acting β2 agonists/inhaled corticosteroids …
muscarinic antagonists (LABA/LAMA) or long-acting β2 agonists/inhaled corticosteroids …
Comparative Effectiveness of Long‐Acting Beta2‐Agonist Combined with a Long‐Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive …
JC Samp, MJ Joo, GT Schumock… - … : The Journal of …, 2017 - Wiley Online Library
Introduction Several dual bronchodilator fixed‐dose inhaler medications were recently
approved for the treatment of chronic obstructive pulmonary disease (COPD). These …
approved for the treatment of chronic obstructive pulmonary disease (COPD). These …
COPD exacerbations and pneumonia hospitalizations in new users of combination maintenance inhalers: a comparative effectiveness and safety study
PURPOSE: Current guidelines recommend inhalers containing long-acting muscarinic
antagonists (LAMA) and long-acting beta agonists (LABA) over inhalers containing inhaled …
antagonists (LAMA) and long-acting beta agonists (LABA) over inhalers containing inhaled …
[HTML][HTML] Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based …
Background Use of combinations of long-acting β2 agonists/long-acting muscarinic
antagonists (LABA/LAMA) in patients with chronic obstructive pulmonary disease (COPD) is …
antagonists (LABA/LAMA) in patients with chronic obstructive pulmonary disease (COPD) is …
[HTML][HTML] A retrospective claims analysis of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in patients with chronic obstructive …
C Strange, V Walker, J Tong, J Kurlander… - … Diseases: Journal of …, 2019 - ncbi.nlm.nih.gov
Introduction: Patients with chronic obstructive pulmonary disease (COPD) increasingly
receive combination bronchodilator therapies. Real world evidence for the benefits of …
receive combination bronchodilator therapies. Real world evidence for the benefits of …
Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
JAE Walters, EH Walters - Cochrane Database of Systematic …, 2023 - cochranelibrary.com
Background Management of chronic obstructive pulmonary disease (COPD) commonly
involves a combination of long‐acting bronchodilators including beta2‐agonists (LABA) and …
involves a combination of long‐acting bronchodilators including beta2‐agonists (LABA) and …
Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled …
CV Asche, S Leader, C Plauschinat… - … journal of chronic …, 2012 - Taylor & Francis
Background To estimate the potential cost savings by following the current Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guideline recommendations in patients being …
for Chronic Obstructive Lung Disease (GOLD) guideline recommendations in patients being …
[HTML][HTML] Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease …
Background Inhaled corticosteroid/long-acting β 2-agonist combinations (ICS/LABA) have
emerged as first line therapies for chronic obstructive pulmonary disease (COPD) patients …
emerged as first line therapies for chronic obstructive pulmonary disease (COPD) patients …
A cost-effectiveness analysis of a first-in-class, triple fixed dose combination therapy against LABA/LAMA therapy in moderate-severe COPD
TB Gosden, A Pitcher, N Nour, A Madoni… - Value in …, 2018 - valueinhealthjournal.com
Objectives For symptomatic chronic obstructive pulmonary disease (COPD) patients who
experience exacerbations, one of the treatments recommended by the 2018 GOLD report is …
experience exacerbations, one of the treatments recommended by the 2018 GOLD report is …
Chronic obstructive pulmonary disease exacerbations and pneumonia hospitalizations among new users of combination maintenance inhalers
Importance Clinical guidelines on chronic obstructive pulmonary disease (COPD)
recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long …
recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long …